Á¾¾çÇÐ ±â¹Ý In-Vivo CRO ½ÃÀå º¸°í¼­ : ÀûÀÀÁõ, ¸ðµ¨, ¿ëµµ, Áö¿ªº°(2025-2033³â)
Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2025-2033
»óǰÄÚµå : 1722713
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 148 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,171,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,561,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,952,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Á¾¾çÇÐ ±â¹Ý In-Vivo CRO ½ÃÀå ±Ô¸ð´Â 2024³â 13¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 24¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 6.55%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ¾Ï À¯º´·ü Áõ°¡, ±ÔÁ¦ Áؼö, Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü, ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõ µîÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Á¾¾çÇÐÀº »ý°Ë, ³»½Ã°æ °Ë»ç, ¿¢½º·¹ÀÌ °Ë»ç, ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CT), ÀÚ±â°ø¸í¿µ»ó(MRI), ¾çÀüÀÚ¹æ»ç¼±´ÜÃþÃÔ¿µ(PET), ÃÊÀ½ÆÄ °Ë»ç µîÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» ¿¬±¸, Áø´Ü, Ä¡·áÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. È£¸£¸ó ¿ä¹ý, ¸é¿ª ¿ä¹ý, ¹æ»ç¼± ¿ä¹ý, °æ±¸ ¿ä¹ýÀ» ȯÀÚ¿¡°Ô Á¦°øÇÏ¿© ¾ÏÀÇ ºÎÀÛ¿ëÀ» °ßµð°í ¿ÏÈ­½Ãŵ´Ï´Ù. ÇöÀç À§Å¹¿¬±¸±â°ü(CRO)ÀÇ ¾Ï Ä¡·á¿ë ÀÓ»ó½ÃÇè¿ë ÀǾàǰ °³¹ß·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î Á¾¾çÇÐ ±â¹Ý In-Vivo CRO¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¾¾çÇÐ ±â¹Ý In-Vivo CRO ½ÃÀå µ¿Çâ :

¼¼°è ¾Ï ¹ßº´·ü Áõ°¡´Â ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°è °¢±¹ Á¤ºÎ´Â ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ´ë±Ô¸ð ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü)ÀÇ ¾Ï Ä¡·á¿¡ ´ëÇÑ Àü¹® Áö½ÄÀÌ Çâ»óµÇ¸é¼­ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¥¿Á½Ã¸®º¸ÇÙ»ê(DNA)À» Á¶ÀÛÇÏ¿© »ý¹°ÀÇ Æ¯¼ºÀ» º¯È­½ÃŰ´Â À¯Àü°øÇÐÀÇ ±â¼ú Çõ½Åµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¼¼Æ÷ÀÇ Áõ½Ä, ¼ºÀå ¹× ºÐÈ­¸¦ Á¦¾îÇϱâ À§ÇÑ ¾Ï À¯ÀüÀÚ ¿¬±¸¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ÇÔ²² ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ÀǾàǰÀÇ ±¤¹üÀ§ÇÑ °¡¿ë¼º°ú ÇコÄÉ¾î »ê¾÷ÀÇ È®ÀåÀº Àü ¼¼°è Á¾¾çÇÐ ºÐ¾ß¿¡¼­ In-Vivo CRO¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, CRO°¡ Á¦°øÇÏ´Â ºñ¿ë È¿À²¼ºÀº ÀÚü ¿¬±¸¿Í ºñ±³ÇÏ¿© ¾÷°è ÅõÀÚÀڵ鿡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÇコÄÉ¾î »ê¾÷Àº ¾Ï ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇϱâ À§ÇØ ¿ø°Ý ÀÇ·á ¹× °¡»ó ÀÓ»ó½ÃÇèÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ Á¾¾çÇÐ ±â¹Ý In-Vivo CRO ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

Á¦7Àå ½ÃÀå ºÐ¼® : ¸ðµ¨º°

Á¦8Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global oncology based in-vivo CRO market size reached USD 1.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.4 Billion by 2033, exhibiting a growth rate (CAGR) of 6.55% during 2025-2033. The rising prevalence of cancer, regulatory compliances, ongoing technological advancements, and the surging demand for personalized medicines are driving the market growth.

Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.

Oncology Based In-Vivo CRO Market Trends:

The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.

Key Market Segmentation:

Breakup by Indication:

Breakup by Model:

Breakup by Application:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Oncology Based In-Vivo CRO Market

6 Market Breakup by Indication

7 Market Breakup by Model

8 Market Breakup by Application

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â